MDWD · MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Market Cap
194.8M
52 Wk Range
$11.80 - $19.70
Previous Close
$13.54
Open
$13.48
Volume
63,751
Day Range
$13.36 - $13.62
Enterprise Value
176.2M
Cash
27.85M
Avg Qtr Burn
-7.65M
Insider Ownership
15.47%
Institutional Own.
54.33%
Qtr Updated
Sep 30th 2026
